Stock Track | Liquidia Technologies Soars 5.37% in Pre-Market on Strong Q1 Earnings Beat and Profit Swing

Stock Track

May 11

Liquidia Technologies Inc's stock soared 5.37% during pre-market trading on Monday, following the release of its first-quarter 2026 financial results.

The biopharmaceutical company reported a significant swing to profitability, with net income of $52.9 million compared to a net loss of $38.4 million in the same period last year. Diluted earnings per share came in at $0.52, beating analyst estimates of $0.41. Revenue surged to $132.9 million, also exceeding expectations of $116.68 million.

The strong performance was primarily driven by sales of YUTREPIA, the company's inhaled dry-powder formulation for pulmonary hypertension. Liquidia reported approximately $130 million in YUTREPIA net product sales, with more than 4,500 unique patient prescriptions and about 3,750 patients started on treatment since its launch. This marks the company's third consecutive quarter of profitability, with improved cash position and continued commercial uptake of its key product.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1166188720"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1166188720\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1166188720?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-11 22:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166188720","market":"nz","top_or_hot":-1,"title":"Stock Track | Liquidia Technologies Soars 5.37% in Pre-Market on Strong Q1 Earnings Beat and Profit Swing","media":"Stock Track","content":"<p>Liquidia Technologies Inc's stock soared 5.37% during pre-market trading on Monday, following the release of its first-quarter 2026 financial results.</p><p>The biopharmaceutical company reported a significant swing to profitability, with net income of $52.9 million compared to a net loss of $38.4 million in the same period last year. Diluted earnings per share came in at $0.52, beating analyst estimates of $0.41. Revenue surged to $132.9 million, also exceeding expectations of $116.68 million.</p><p>The strong performance was primarily driven by sales of YUTREPIA, the company's inhaled dry-powder formulation for pulmonary hypertension. Liquidia reported approximately $130 million in YUTREPIA net product sales, with more than 4,500 unique patient prescriptions and about 3,750 patients started on treatment since its launch. This marks the company's third consecutive quarter of profitability, with improved cash position and continued commercial uptake of its key product.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Liquidia Technologies Soars 5.37% in Pre-Market on Strong Q1 Earnings Beat and Profit Swing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Liquidia Technologies Soars 5.37% in Pre-Market on Strong Q1 Earnings Beat and Profit Swing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-11 22:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Liquidia Technologies Inc's stock soared 5.37% during pre-market trading on Monday, following the release of its first-quarter 2026 financial results.</p><p>The biopharmaceutical company reported a significant swing to profitability, with net income of $52.9 million compared to a net loss of $38.4 million in the same period last year. Diluted earnings per share came in at $0.52, beating analyst estimates of $0.41. Revenue surged to $132.9 million, also exceeding expectations of $116.68 million.</p><p>The strong performance was primarily driven by sales of YUTREPIA, the company's inhaled dry-powder formulation for pulmonary hypertension. Liquidia reported approximately $130 million in YUTREPIA net product sales, with more than 4,500 unique patient prescriptions and about 3,750 patients started on treatment since its launch. This marks the company's third consecutive quarter of profitability, with improved cash position and continued commercial uptake of its key product.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LQDA","symbol_name":"Liquidia Technologies Inc","start_time":0,"source_url":"","article_id":"1166188720","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166188720","pubTimestamp":1778508858,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Liquidia Technologies Inc's stock soared 5.37% during pre-market trading on Monday, following the release of its first-quarter 2026 financial results.The biopharmaceutical company reported a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LQDA":"Liquidia Technologies Inc"},"translate_title":"个股追踪|Liquidia Technologies盘前飙升5.37%，因Q1盈利强劲增长和利润波动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LQDA":1},"content_text":"Liquidia Technologies Inc's stock soared 5.37% during pre-market trading on Monday, following the release of its first-quarter 2026 financial results.The biopharmaceutical company reported a significant swing to profitability, with net income of $52.9 million compared to a net loss of $38.4 million in the same period last year. Diluted earnings per share came in at $0.52, beating analyst estimates of $0.41. Revenue surged to $132.9 million, also exceeding expectations of $116.68 million.The strong performance was primarily driven by sales of YUTREPIA, the company's inhaled dry-powder formulation for pulmonary hypertension. Liquidia reported approximately $130 million in YUTREPIA net product sales, with more than 4,500 unique patient prescriptions and about 3,750 patients started on treatment since its launch. This marks the company's third consecutive quarter of profitability, with improved cash position and continued commercial uptake of its key product.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}